Melanoma

Resectable
Stage III-IV

Neoadjuvant /Adjuvant

ECOG-ACRIN-S1801
Phase II Adjuvant vs NeoAdjuvant MK-3475 (Pembrolizumab) in Stage III-IV High-Risk Melanoma
PI: Reddy
ECOG ACRIN

Unresectable
Stage III-IV

Any Line
1st Line
Previously treated with PD-1

MEL0026
Phase III NKTR-214 +Nivolumab vsNivolumab in Previously Untreated /Unresectable /Metastatic Melanoma
PI: Reddy
Bristol Myers Squibb

CCT5055
A Phase II, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects with Advanced Melanoma (Instil Bio Study ITIL-168-101)
PI: Instill Bio
Bristol Myers Squibb

KEY
- - Optional Path
Link
Trial Posting
- - Extension Study
- - Immunotherapy
Pending
Open for Enrollment
Observational Study
Enrollment on Hold